0001209191-24-005118.txt : 20240327 0001209191-24-005118.hdr.sgml : 20240327 20240327205215 ACCESSION NUMBER: 0001209191-24-005118 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240327 FILED AS OF DATE: 20240327 DATE AS OF CHANGE: 20240327 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mancini Marianna CENTRAL INDEX KEY: 0001838112 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37355 FILM NUMBER: 24793071 MAIL ADDRESS: STREET 1: C/O VIKING THERAPEUTICS, INC. STREET 2: 12340 EL CAMINO REAL, STE 250 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Viking Therapeutics, Inc. CENTRAL INDEX KEY: 0001607678 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 461073877 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-704-4660 MAIL ADDRESS: STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2024-03-27 0 0001607678 Viking Therapeutics, Inc. VKTX 0001838112 Mancini Marianna C/O VIKING THERAPEUTICS, INC. 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 0 1 0 0 Chief Operating Officer 0 Common Stock, par value $0.00001 per share 2024-03-27 4 A 0 31667 0.00 A 380175 D Common Stock, par value $0.00001 per share 2024-03-27 4 F 0 16610 83.34 D 363565 D The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on March 27, 2024 upon the achievement of a non-financial performance goal. These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units. /s/ Michael Morneau, as Attorney-in-Fact 2024-03-27